For example, over half of breast cancers demonstrate upregulated markers of mTORC1 activation, such as phospho-S6K1 and phospho-ribosomal protein S6 (rpS6) [2, 3], while overexpression of mTORC1 substrates are also strongly associated with prostate cancer [4]. Here, RPS6 is linked to prostate carcinoma.